Body surface potential mapping detected abnormal amplitudes beyond the 12-lead electrocardiogram in presymptomatic carriers, with a maximal increase in frequency of 31% during follow-up.
Observational
Does body surface potential mapping (BSPM) detect local electrical abnormalities earlier than the 12-lead electrocardiogram in pathogenic variant carriers of phospholamban and plakophilin-2 cardiomyopathy?
Body surface potential mapping can detect abnormal electrical amplitudes earlier than standard 12-lead ECGs in presymptomatic carriers of arrhythmogenic cardiomyopathy variants, potentially aiding in early disease detection.
Background: ) are associated with arrhythmogenic cardiomyopathy. Early disease detection is important to prevent adverse events. Body surface potential mapping (BSPM) may detect local electrical abnormalities earlier than the 12-lead electrocardiogram. Objective: pathogenic variant carriers using BSPM. Methods: carriers. R-, S-, and T-wave amplitudes across all leads in controls were used as reference. Amplitudes of carriers exceeding these ranges were considered abnormal and assessed across disease stages (presymptomatic, electrical, and structural, as done previously). Follow-up BSPM (≥2 years) was performed in a subset of carriers. Results: ) showed consistency in locations of abnormalities with increased frequency (maximal increase 31%). Conclusion: BSPM detected abnormal amplitudes within and beyond the 12-lead electrocardiogram, even in presymptomatic carriers. Follow-up BSPM suggests that these abnormalities are associated with disease progression, highlighting the potential benefit of BSPM in early disease detection.
Schaaf et al. (Sat,) conducted a observational in Phospholamban and plakophilin-2 cardiomyopathy. Body surface potential mapping (BSPM) vs. 12-lead electrocardiogram was evaluated on Abnormal R-, S-, and T-wave amplitudes. Body surface potential mapping detected abnormal amplitudes beyond the 12-lead electrocardiogram in presymptomatic carriers, with a maximal increase in frequency of 31% during follow-up.